Anagliptin

DB12417InvestigationalSmall molecule

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

Mechanism: Pharmacologically active on Dipeptidyl peptidase 4
Curator reviewed
Formula / weight: C₁₉H₂₅N₇O₂ · 383.456 g/mol (avg)
Code names: CWP-403 · SK-0403

Resolves to

Compound

UNIIK726J96838CAS739366-20-2ChEMBLCHEMBL1929396ChEBI136043PubChem44513473

Structure

InChIKeyLDXYBEHACFJIEL-HNNXBMFYSA-NSMILESCC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N

Targets

P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

656Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anagliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account